                         SEQUENCE LISTING

<110>  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW 
       UNIVERSITY OF JERUSALEM LTD.
 
<120>  E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 
       AGENTS

<130>  HUJI-P-059-PCT

<150>  63/018,598
<151>  2020-05-01

<150>  63/117,619
<151>  2020-11-24

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  75
<212>  PRT
<213>  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

<400>  1

Met Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser 
1               5                   10                  15      


Val Leu Leu Phe Leu Ala Phe Val Val Phe Leu Leu Val Thr Leu Ala 
            20                  25                  30          


Ile Leu Thr Ala Leu Arg Leu Cys Ala Tyr Cys Cys Asn Ile Val Asn 
        35                  40                  45              


Val Ser Leu Val Lys Pro Ser Phe Tyr Val Tyr Ser Arg Val Lys Asn 
    50                  55                  60                  


Leu Asn Ser Ser Arg Val Pro Asp Leu Leu Val 
65                  70                  75  


<210>  2
<211>  275
<212>  PRT
<213>  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

<400>  2

Met Asp Leu Phe Met Arg Ile Phe Thr Ile Gly Thr Val Thr Leu Lys 
1               5                   10                  15      


Gln Gly Glu Ile Lys Asp Ala Thr Pro Ser Asp Phe Val Arg Ala Thr 
            20                  25                  30          


Ala Thr Ile Pro Ile Gln Ala Ser Leu Pro Phe Gly Trp Leu Ile Val 
        35                  40                  45              


Gly Val Ala Leu Leu Ala Val Phe Gln Ser Ala Ser Lys Ile Ile Thr 
    50                  55                  60                  


Leu Lys Lys Arg Trp Gln Leu Ala Leu Ser Lys Gly Val His Phe Val 
65                  70                  75                  80  


Cys Asn Leu Leu Leu Leu Phe Val Thr Val Tyr Ser His Leu Leu Leu 
                85                  90                  95      


Val Ala Ala Gly Leu Glu Ala Pro Phe Leu Tyr Leu Tyr Ala Leu Val 
            100                 105                 110         


Tyr Phe Leu Gln Ser Ile Asn Phe Val Arg Ile Ile Met Arg Leu Trp 
        115                 120                 125             


Leu Cys Trp Lys Cys Arg Ser Lys Asn Pro Leu Leu Tyr Asp Ala Asn 
    130                 135                 140                 


Tyr Phe Leu Cys Trp His Thr Asn Cys Tyr Asp Tyr Cys Ile Pro Tyr 
145                 150                 155                 160 


Asn Ser Val Thr Ser Ser Ile Val Ile Thr Ser Gly Asp Gly Thr Thr 
                165                 170                 175     


Ser Pro Ile Ser Glu His Asp Tyr Gln Ile Gly Gly Tyr Thr Glu Lys 
            180                 185                 190         


Trp Glu Ser Gly Val Lys Asp Cys Val Val Leu His Ser Tyr Phe Thr 
        195                 200                 205             


Ser Asp Tyr Tyr Gln Leu Tyr Ser Thr Gln Leu Ser Thr Asp Thr Gly 
    210                 215                 220                 


Val Glu His Val Thr Phe Phe Ile Tyr Asn Lys Ile Val Asp Glu Pro 
225                 230                 235                 240 


Glu Glu His Val Gln Ile His Thr Ile Asp Gly Ser Ser Gly Val Val 
                245                 250                 255     


Asn Pro Val Met Glu Pro Ile Tyr Asp Glu Pro Thr Thr Thr Thr Ser 
            260                 265                 270         


Val Pro Leu 
        275 


